GKOS

Glaukos Q4 Prelim Sales Climb Above Estimates; Backs Annual Revenue Outlook

(RTTNews) - Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company, on Tuesday reported a rise in preliminary sales for the fourth-quarter and full year.

In addition, the company has reaffirmed its full-year 2024 revenue outlook.

For the fourth-quarter, the company posted preliminary sales of over $81 million, compared with $71.227 million reported for the same period last year.

On average, 12 analysts polled by Thomson Reuters expect the firm to record revenue of $76.66 million, for the quarter.

For the full year, Glaukos recorded preliminary sales of over $313 million, higher than $282.862 million a year ago. Analysts, on average, project the company to post sales of $309.02 million, for the year.

For the twelve-month period, the company still expects to register sales of $350 million to $360 million, in line with analysts' estimate of $352.71 million.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.